Presentation is loading. Please wait.

Presentation is loading. Please wait.

Sarcomatoid Carcinoma of the Lung: A Predictor of Poor Prognosis

Published byLeslie Gilbert Modified over 6 years ago

Similar presentations

Presentation on theme: "Sarcomatoid Carcinoma of the Lung: A Predictor of Poor Prognosis"— Presentation transcript:

1 Sarcomatoid Carcinoma of the Lung: A Predictor of Poor Prognosis
Linda W. Martin, MD, MPH, Arlene M. Correa, PhD, Nelson G. Ordonez, MD, Jack A. Roth, MD, Stephen G. Swisher, MD, Ara A. Vaporciyan, MD, Garrett L. Walsh, MD, David C. Rice, MB, BCh  The Annals of Thoracic Surgery  Volume 84, Issue 3, Pages (September 2007) DOI: /j.athoracsur Copyright © 2007 The Society of Thoracic Surgeons Terms and Conditions

2 Fig 1 Survival after treatment initiation for 1133 patients with unmatched non-small cell lung cancer (NSCLC, solid line) and 63 patients with sarcomatoid carcinoma (SARC, dashed line). The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur ) Copyright © 2007 The Society of Thoracic Surgeons Terms and Conditions

3 Fig 2 Survival after treatment initiation in propensity-matched patients with sarcomatoid carcinoma (SARC, dashed line; n = 63) and non-small cell lung cancer (NSCLC, solid line; n = 63). The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur ) Copyright © 2007 The Society of Thoracic Surgeons Terms and Conditions

4 Fig 3 Survival after treatment initiation in propensity-matched patients with sarcomatoid carcinoma (SARC, dashed line) and non-small cell lung cancer (NSCLC, solid line) for each pathologic stage: (A) I; (B) II; (C) III; (D) IV. The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur ) Copyright © 2007 The Society of Thoracic Surgeons Terms and Conditions

5 Fig 4 Freedom from recurrent cancer for propensity-matched patients with sarcomatoid carcinoma (SARC, dashed line; n = 63) and non-small cell lung cancer (NSCLC, solid line; n = 63). The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur ) Copyright © 2007 The Society of Thoracic Surgeons Terms and Conditions

Download ppt "Sarcomatoid Carcinoma of the Lung: A Predictor of Poor Prognosis"

Similar presentations

The evolution of treatment outcomes for resected stage IIIA non–small cell lung cancer over 16 years at a single institution  Linda W. Martin, MD, Arlene.

The evolution of treatment outcomes for resected stage IIIA non–small cell lung cancer over 16 years at a single institution  Linda W. Martin, MD, Arlene.
Definitive or Preoperative Chemoradiation Therapy for Esophageal Cancer: Patterns of Care and Survival Outcomes  Meng S. Shao, MD, Andrew T. Wong, MD,

Definitive or Preoperative Chemoradiation Therapy for Esophageal Cancer: Patterns of Care and Survival Outcomes  Meng S. Shao, MD, Andrew T. Wong, MD,
Lymphovascular Invasion as a Prognostic Indicator in Stage I Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis  Nathan M. Mollberg, DO,

Lymphovascular Invasion as a Prognostic Indicator in Stage I Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis  Nathan M. Mollberg, DO,
A Propensity-Matched Analysis of Wedge Resection and Stereotactic Body Radiotherapy for Early Stage Lung Cancer  Jeffrey L. Port, MD, Bhupesh Parashar,

A Propensity-Matched Analysis of Wedge Resection and Stereotactic Body Radiotherapy for Early Stage Lung Cancer  Jeffrey L. Port, MD, Bhupesh Parashar,
Survival After Surgical Resection for Lung Cancer in Patients With Chronic Obstructive Pulmonary Disease  Anders Bugge, MD, May Brit Lund, MD, PhD, Cathrine.

Survival After Surgical Resection for Lung Cancer in Patients With Chronic Obstructive Pulmonary Disease  Anders Bugge, MD, May Brit Lund, MD, PhD, Cathrine.
Complete Thoracic Mediastinal Lymphadenectomy Leads to a Higher Rate of Pathologically Proven N2 Disease in Patients With Non-Small Cell Lung Cancer 

Complete Thoracic Mediastinal Lymphadenectomy Leads to a Higher Rate of Pathologically Proven N2 Disease in Patients With Non-Small Cell Lung Cancer 
Melanie Subramanian, MD, Timothy McMurry, PhD, Bryan F

Melanie Subramanian, MD, Timothy McMurry, PhD, Bryan F
Comparison of Thoracoscopic Segmentectomy and Thoracoscopic Lobectomy for Small-Sized Stage IA Lung Cancer  Chenxi Zhong, MD, Wentao Fang, MD, Teng Mao,

Comparison of Thoracoscopic Segmentectomy and Thoracoscopic Lobectomy for Small-Sized Stage IA Lung Cancer  Chenxi Zhong, MD, Wentao Fang, MD, Teng Mao,
Survival on the Heart Transplant Waiting List: Impact of Continuous Flow Left Ventricular Assist Device as Bridge to Transplant  Jaimin R. Trivedi, MD,

Survival on the Heart Transplant Waiting List: Impact of Continuous Flow Left Ventricular Assist Device as Bridge to Transplant  Jaimin R. Trivedi, MD,
Utility of PET, CT, and EUS to Identify Pathologic Responders in Esophageal Cancer  Stephen G. Swisher, MD, Mary Maish, MD, Jeremy J. Erasmus, MD, Arlene.

Utility of PET, CT, and EUS to Identify Pathologic Responders in Esophageal Cancer  Stephen G. Swisher, MD, Mary Maish, MD, Jeremy J. Erasmus, MD, Arlene.
Joshua E. Rosen, BASc, Hari B

Joshua E. Rosen, BASc, Hari B
Puja Gaur, MD, Wayne L. Hofstetter, MD, B

Puja Gaur, MD, Wayne L. Hofstetter, MD, B
Lisa M. Brown, MD, MAS, David T. Cooke, MD, Elizabeth A. David, MD 

Lisa M. Brown, MD, MAS, David T. Cooke, MD, Elizabeth A. David, MD 
Clinical Prognosis of Superior Versus Basal Segment Stage I Non-Small Cell Lung Cancer  Yoshinori Handa, MD, Yasuhiro Tsutani, MD, PhD, Norifumi Tsubokawa,

Clinical Prognosis of Superior Versus Basal Segment Stage I Non-Small Cell Lung Cancer  Yoshinori Handa, MD, Yasuhiro Tsutani, MD, PhD, Norifumi Tsubokawa,
Application of the revised lung cancer staging system (IASLC Staging Project) to a cancer center population  Edmund S. Kassis, MD, Ara A. Vaporciyan,

Application of the revised lung cancer staging system (IASLC Staging Project) to a cancer center population  Edmund S. Kassis, MD, Ara A. Vaporciyan,
Morbidity, Survival, and Site of Recurrence After Mediastinal Lymph-Node Dissection Versus Systematic Sampling After Complete Resection for Non-Small.

Morbidity, Survival, and Site of Recurrence After Mediastinal Lymph-Node Dissection Versus Systematic Sampling After Complete Resection for Non-Small.
Benjamin E. Lee, MD, Mark Shapiro, MD, John R. Rutledge, MAS, Robert J

Benjamin E. Lee, MD, Mark Shapiro, MD, John R. Rutledge, MAS, Robert J
Histopathologic Response Criteria Predict Survival of Patients with Resected Lung Cancer After Neoadjuvant Chemotherapy  Apar Pataer, MD, PhD, Neda Kalhor,

Histopathologic Response Criteria Predict Survival of Patients with Resected Lung Cancer After Neoadjuvant Chemotherapy  Apar Pataer, MD, PhD, Neda Kalhor,
A Model to Predict the Use of Surgical Resection for Advanced-Stage Non-Small Cell Lung Cancer Patients  Elizabeth A. David, MD, Stina W. Andersen, PhD,

A Model to Predict the Use of Surgical Resection for Advanced-Stage Non-Small Cell Lung Cancer Patients  Elizabeth A. David, MD, Stina W. Andersen, PhD,
Video-Assisted Thoracic Surgery Lobectomy: Experience With 1,100 Cases

Video-Assisted Thoracic Surgery Lobectomy: Experience With 1,100 Cases

Similar presentations

Ads by Google